Barclays Sees Renal IgAN Growth, Sets $606 Target on Vertex
Barclays initiated coverage of Vertex Pharmaceuticals with an Overweight rating and $606 price target, highlighting the renal IgAN program as a growth driver with data expected early this year. It cited strong cystic fibrosis cash flows to fund development and said Journavx prescription and revenue gains in 2026 are underappreciated.
1. Barclays Initiates Overweight Rating
Barclays began coverage of Vertex Pharmaceuticals with an Overweight rating and set a $606 price target, citing the company’s expanding renal pipeline as a key valuation driver.
2. Renal IgAN Program Potential
Analysts expect Vertex’s immunoglobulin A nephropathy program to deliver encouraging clinical results early this year, positioning the renal franchise for a multi-billion-dollar market opportunity.
3. CF Therapy Cash Flow Support
Vertex’s established cystic fibrosis therapies generate robust cash flows that Barclays forecasts will fund ongoing research and commercialization of the renal pipeline.
4. Journavx Prescription and Revenue Growth
Barclays highlighted that increases in Journavx prescriptions and corresponding revenue gains projected for 2026 have been largely overlooked by investors.